Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Latest News
Underlying PBS growth less than 3%
Reimbursement: The PBS headline growth is 17.5% according to the latest stats but take out new hep C drugs and it's a different story.
PBS reform gains slipping away
Reimbursement: 'Robbing Peter to pay Paul' in the PBS will soon no longer be enough to make the scheme sustainable senior pharma execs have said.
Anmeal promises $75K boost to pharmacies
Generics: Generics company celebrates two years in Australia with a proprietary dose administration aid it says can boost pharmacy margins.
Pharmaxis surges on Russian approval
Exports: Company's shares skyrocket on the news that the Australian drug is the first to receive marketing approval under Russia's new orphan drug legislation.
GPs want to dispense medicines
Pharmacy Review: The peak GP body has used its Pharmacy Remuneration Review submission to suggest late night surgery dispensing is better than using financial incentives to keep pharmacies open later.
MyDNA targets mental health drugs
Pharmacogenomics: After hitting a speedbump when Chemmart was required by the ACCC to withdraw its marketing material, MyDNA is targeting mental health practitioners and patients.
Most Popular
Pfizer decides not to split
Companies: After years of speculation Pfizer has announced it will not split itself into two separate companies.
Roundtable seeks way forward for 'disconnected' Aussie pharma
Exclusive - Government Relations: Last Friday, Pharma in Focus convened a roundtable of senior industry executives to address Aussie pharma's troubled relationship with government. With help from former PM and Health Minister Tony Abbott, the event delivered new clarity around troubling issues and proposed solutions.
Biosim awareness: Drs may get incentive
Biosimilars: Plans are underway to possibly tie continuing professional development points to biosimilar education for HCPs.
Consumer boss to lead GSK global
Leadership: GSK Consumer boss, Emma Walmsley, has been tapped to take over as global CEO when Andrew Witty retires in March next year.
Merger will shrink role of Bayer pharma
Mergers: When Bayer and Monsanto merge, healthcare, which used to provide over two thirds of revenue, will generate less than half.
Smoke and mirrors behind political message on Oct PBS price cuts
Reimbursement: Determined to maximise any political advantage from medicine price cuts, the government is playing smoke and mirrors with its public messages.
Black-box PBS feeding mistrust
Reimbursement: Lack of transparency in PBS processes has become a major challenge for pharma in Australia, senior executives say.
Execs tell why pharma is shrinking
Industry Roundtable: Aussie pharma is shrinking as price disclosure mechanisms cause products to be withdrawn, clinical trial costs rise and research increasingly moves offshore.
Merck awards growth researcher
Philanthropy: A University of Queensland researcher has been awarded in the prestigious international Merck Grant for Growth Innovation program.
AP gastric cancer market to double
Market Trends: Greater awareness and detection of gastric cancer combined with improving health insurance and more targeted treatments are all driving market growth in the Asia-Pacific region.
Debating Point
PBS restructure: essential but impossible?
Pharma in Focus' executive roundtable held last Friday revealed significant reasons why the PBS is in need of a thoroughgoing restructure but also exposed why it may be impossible to achieve.
Approvals Action
Janssen, BMS, Biogen, CSL boost portfolios
The drugs register has seen a good deal of activity during the week with five new products being approved including new doses of existing drugs.
Pipeline Monitor
First therapy for Duchenne muscular dystrophy
FDA green lights first therapy for Duchenne muscular dystrophy while Opdivo moves towards a sixth indication in Europe and CHMP releases new approval advice.
Debating Point
Reg reform: even if it's good, it's only half the job
As industry braces for three years of regulatory reform, welcome as it may be, the question arises whether, for medicines access it's only half the job that needs to be done.
FREE Content
Events & Conferences
Pharma in Focus Jobs
Brooker Consulting